Printer Friendly

AIDS drug sparks concern.

AIDS drug sparks concern

In some patients, the experimental AIDS drug dideoxyinosine (DDI) appears to increase the risk of death from pancreatitis, an inflammation of the pancreas. Researchers expressed concern about the link last week after DDI manufacturer Bristol-Myers Squibb Co. of New York City said six AIDS patients taking DDI had died of pancreatitis and that five of those were enrolled in a federally approved program that allows widespread distribution of DDI.

About 8,000 people with AIDS took advantage of the Food and Drug Administration's decision last fall to approve the expanded-access program, which allows Bristol-Myers Squibb to provide DDI to severely ill AIDS patients who fail to qualify for clinical DDI trials (SN: 10/7/89, p.231). Participating patients get DDI from private physicians who agree to inform the manufacturer of any problems. Now Bristol-Myers Squibb reports 290 deaths out of 8,000 people enrolled in the program, with five of those deaths due to pancreatitis, says spokeswoman Kathryn Bloom. In contrast, the company reports two deaths (one due to pancreatitis) among the 700 AIDS patients enrolled in Phase II clinical trials.

"Bad news like this makes you want to look more closely at how [the access program] is being administered," says Jeffrey Laurence of the Cornell University Medical College in New York City. Bloom contends the higher overall death rate among expanded-access patients stems from the severity of their illness upon entering the program.
COPYRIGHT 1990 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1990, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:dideoxyinosine
Publication:Science News
Date:Mar 17, 1990
Words:239
Previous Article:School program cuts adolescent drug use.
Next Article:Oxygen plays role in cancer aggressiveness.
Topics:


Related Articles
AIDS drug shows promise.
Gout drug might cut AZT dosage by half.
FDA broadens use of unproven AIDS drug.
AIDS predictors; can new laboratory markers speed the approval of AIDS drugs?
AIDS drug passes preliminaries.
Receptor decoy shows promise against AIDS.
Panel backs DDI despite uncertainties.
No survival bonus from early AZT.
The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters